Regenxbio (RGNX) Misses Q1 EPS by 15c

Regenxbio (NASDAQ: RGNX) reported Q1 EPS of ($1.53), $0.15 worse than the analyst estimate of ($1.38). Revenue for the quarter came in at $19.14 million versus the consensus estimate of $31.97 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Medtronic completes $550 million Scientia Vascular acquisition
• UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results